San Diego-based Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February following revealing promising information from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the com